Tags

Type your tag names separated by a space and hit enter

Ceftolozane/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012).
Int J Antimicrob Agents. 2014 Jun; 43(6):533-9.IJ

Abstract

During 2012, a total of 2968 isolates were consecutively collected from 59 medical centres in the USA and 15 European countries from hospitalised patients with pneumonia. Ceftolozane/tazobactam (tazobactam at a fixed concentration of 4mg/L) and comparator agents were tested by reference methods, and MIC endpoints were interpreted by CLSI (2013) and EUCAST (2013) breakpoint criteria. Pseudomonas aeruginosa was the most common isolated pathogen (1019 strains; 34.3%), and ceftolozane/tazobactam was the most active β-lactam tested against P. aeruginosa (MIC50/90, 0.5/4 mg/L; 94.1% inhibited at ≤ 8 mg/L). P. aeruginosa exhibited moderate susceptibility to meropenem (MIC50/90, 0.5/>8 mg/L; 73.7% susceptible), ceftazidime (MIC50/90, 2/>32 mg/L; 73.6% susceptible), cefepime (MIC50/90, 4/>16 mg/L; 76.5% susceptible), piperacillin/tazobactam (MIC50/90, 8/>64 mg/L; 69.5% susceptible), levofloxacin [MIC50/90, 0.5/>4 mg/L; 69.9/61.0% susceptible (CLSI/EUCAST criteria)] and gentamicin (MIC50/90, 2/>8 mg/L; 80.7% susceptible). Ceftolozane/tazobactam exhibited activity against many ceftazidime-non-susceptible, meropenem-non-susceptible and piperacillin/tazobactam-non-susceptible, multidrug-resistant (MDR) and extensively drug-resistant (XDR) P. aeruginosa isolates. Ceftolozane/tazobactam was active (MIC50/90, 0.25/4mg/L; 94.6% inhibited at ≤ 8 mg/L) against 1530 Enterobacteriaceae, including activity against many MDR and XDR strains. MDR and XDR prevalence varied widely between countries both for P. aeruginosa (24.1% MDR and 17.1% XDR overall) and Enterobacteriaceae (15.4% MDR and 2.7% XDR overall). All β-lactams had limited activity against Acinetobacter spp. and Stenotrophomonas maltophilia. Ceftolozane/tazobactam demonstrated greater in vitro activity than currently available cephalosporins, carbapenems and piperacillin/tazobactam when tested against P. aeruginosa. In addition, ceftolozane/tazobactam demonstrated greater activity than contemporary cephalosporins and piperacillin/tazobactam when tested against most Enterobacteriaceae.

Authors+Show Affiliations

JMI Laboratories, 345 Beaver Kreek Center, Suite A, North Liberty, IA 52317, USA. Electronic address: david-farrell@jmilabs.com.JMI Laboratories, 345 Beaver Kreek Center, Suite A, North Liberty, IA 52317, USA.JMI Laboratories, 345 Beaver Kreek Center, Suite A, North Liberty, IA 52317, USA.JMI Laboratories, 345 Beaver Kreek Center, Suite A, North Liberty, IA 52317, USA.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

24856078

Citation

Farrell, David J., et al. "Ceftolozane/tazobactam Activity Tested Against Gram-negative Bacterial Isolates From Hospitalised Patients With Pneumonia in US and European Medical Centres (2012)." International Journal of Antimicrobial Agents, vol. 43, no. 6, 2014, pp. 533-9.
Farrell DJ, Sader HS, Flamm RK, et al. Ceftolozane/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012). Int J Antimicrob Agents. 2014;43(6):533-9.
Farrell, D. J., Sader, H. S., Flamm, R. K., & Jones, R. N. (2014). Ceftolozane/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012). International Journal of Antimicrobial Agents, 43(6), 533-9. https://doi.org/10.1016/j.ijantimicag.2014.01.032
Farrell DJ, et al. Ceftolozane/tazobactam Activity Tested Against Gram-negative Bacterial Isolates From Hospitalised Patients With Pneumonia in US and European Medical Centres (2012). Int J Antimicrob Agents. 2014;43(6):533-9. PubMed PMID: 24856078.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Ceftolozane/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012). AU - Farrell,David J, AU - Sader,Helio S, AU - Flamm,Robert K, AU - Jones,Ronald N, Y1 - 2014/03/26/ PY - 2013/11/07/received PY - 2014/01/24/revised PY - 2014/01/27/accepted PY - 2014/5/27/entrez PY - 2014/5/27/pubmed PY - 2015/1/17/medline KW - Ceftolozane/tazobactam KW - Nosocomial KW - Pneumonia KW - Surveillance SP - 533 EP - 9 JF - International journal of antimicrobial agents JO - Int J Antimicrob Agents VL - 43 IS - 6 N2 - During 2012, a total of 2968 isolates were consecutively collected from 59 medical centres in the USA and 15 European countries from hospitalised patients with pneumonia. Ceftolozane/tazobactam (tazobactam at a fixed concentration of 4mg/L) and comparator agents were tested by reference methods, and MIC endpoints were interpreted by CLSI (2013) and EUCAST (2013) breakpoint criteria. Pseudomonas aeruginosa was the most common isolated pathogen (1019 strains; 34.3%), and ceftolozane/tazobactam was the most active β-lactam tested against P. aeruginosa (MIC50/90, 0.5/4 mg/L; 94.1% inhibited at ≤ 8 mg/L). P. aeruginosa exhibited moderate susceptibility to meropenem (MIC50/90, 0.5/>8 mg/L; 73.7% susceptible), ceftazidime (MIC50/90, 2/>32 mg/L; 73.6% susceptible), cefepime (MIC50/90, 4/>16 mg/L; 76.5% susceptible), piperacillin/tazobactam (MIC50/90, 8/>64 mg/L; 69.5% susceptible), levofloxacin [MIC50/90, 0.5/>4 mg/L; 69.9/61.0% susceptible (CLSI/EUCAST criteria)] and gentamicin (MIC50/90, 2/>8 mg/L; 80.7% susceptible). Ceftolozane/tazobactam exhibited activity against many ceftazidime-non-susceptible, meropenem-non-susceptible and piperacillin/tazobactam-non-susceptible, multidrug-resistant (MDR) and extensively drug-resistant (XDR) P. aeruginosa isolates. Ceftolozane/tazobactam was active (MIC50/90, 0.25/4mg/L; 94.6% inhibited at ≤ 8 mg/L) against 1530 Enterobacteriaceae, including activity against many MDR and XDR strains. MDR and XDR prevalence varied widely between countries both for P. aeruginosa (24.1% MDR and 17.1% XDR overall) and Enterobacteriaceae (15.4% MDR and 2.7% XDR overall). All β-lactams had limited activity against Acinetobacter spp. and Stenotrophomonas maltophilia. Ceftolozane/tazobactam demonstrated greater in vitro activity than currently available cephalosporins, carbapenems and piperacillin/tazobactam when tested against P. aeruginosa. In addition, ceftolozane/tazobactam demonstrated greater activity than contemporary cephalosporins and piperacillin/tazobactam when tested against most Enterobacteriaceae. SN - 1872-7913 UR - https://www.unboundmedicine.com/medline/citation/24856078/Ceftolozane/tazobactam_activity_tested_against_Gram_negative_bacterial_isolates_from_hospitalised_patients_with_pneumonia_in_US_and_European_medical_centres__2012__ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0924-8579(14)00068-5 DB - PRIME DP - Unbound Medicine ER -